ASAM 55th Annual Conference
April 4-7, 2024 | Dallas, TX

Pre-Conference Courses
April 4, 2024 | 9:00 am - 4:30 pm

WOMEN & ADDICTION: Screening, Treatment, and Whole Person Care

PAIN & ADDICTION: Common Threads XXV

More information in the app!
Conference Organizers

Annual Conference Program Planning Committee
Anika A. H. Alvanzo, MD, MS, FACP, DFASAM (Chair)
Nassima Ait-daoud Tiouririne, MD, FASAM
Saad Alvi, MD
Fiona Axelsson, MD
Subhadeep Barman, MD, FAPA, FASCP, FASAM
Ricky Bluthenthal, PhD
Julie W. Childers, MD
Nicholaus Christian, MD, MBA
Jeremiah Fairbanks, DO
Oluwaseun Falade-Nwulia, MBBS, MPH
Michael Fingerhood, MD, FACP, DFASAM
Sabrina Gill, MD
Jason D. Kirby, DO, MBA, FASAM
Gregg Lund, DO, MS, FAAP, FASAM
Vita McCabe, MD, MHSA
Kylie Morris, DO
Lewis S. Nelson, MD, DFASAM
Debra W. Obeirne, MD, FASAM
Awawu Ojikutu, CRNP
Jeanmarie Perrone, MD
Lee Radosh, MD, FAAP, FASAM
Kelly S. Ramsey, MD, MPH, MA, FACP, DFASAM
Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, FACP, DFASAM
Evon Schwarz, MD
Robert C. Sherrick, MD, FASAM
Kento Sonoda, MD, AAHIVS, FASAM
Steven Tate, MD, MSc
J. Deanna Wilson, MD, MPH, FASAM

Annual Conference Abstract Reviewers
Anthony J. Accurso, MD
Michael Argenyi, MD, MPH, MSW
Alyssa Bottrell, MD, PhD
Julie Byler, DO
Keri Holmes Maybank, MD, MSCR, SFHM
Ashly Jordan, PhD, MPH
JoAn Laes, MD, FACMT, DFASAM
Stephen Martin, MD
Nathan Menke, MD, PhD
Priscilla Ohuoha, MSW, EdD, MPH
Rikinkumar Patel, MD, MPH
Alaina R. Steck, MD, FACMT, FASAM
Brendan Sullivan, DO
Stephanie Weiss, MD, PhD

ASAM CE Committee & Reviewers
Cara A. Poland, MD, MEd, DFASAM (Chair)
Jennifer Aldea, PA-C
Catharina Armstrong, MD, FASAM
Subhadeep Barman, MD, FAPA, FASCP, FASAM
Benjamin Bearnot, MD, MPH, FASAM
Arianna Campbell, PA-C
Herbert L. Malinoff, MD, FACP, DFASAM
John D. Perra, LCSW
Edwin A. Salsitz, MD, DFASAM
Pamela J. Shultz, MD, FASAM
Eman Warraich-Gibson, MSW
Mark A. Weiner, MD, DFASAM

Agency Representatives
Yngvild Olsen, MD, MPH, DFASAM (SAMHSA Liaison)
Deidra Roach, MD (NIAAA Liaison)
Geetha Subramaniam, MD (NIDA Liaison)

Login for free WiFi!
Network: ASAM2024  Password: ASAM2024
The full conference schedule, including speaker information, presentation slides, and more is available on the conference website (https://annualconference.asam.org/) and in the ASAM Events app.

### Pre-Conference Activities

**Wednesday, April 3**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:00 pm – 8:00 pm</td>
<td>ASAM Registration Open</td>
<td>Center Pre-Function, Level 3</td>
</tr>
<tr>
<td>9:00 pm – 10:00 pm</td>
<td>Mutual Help (Open Meeting)</td>
<td>Del Rio 2, Level 1</td>
</tr>
</tbody>
</table>

**Thursday, April 4**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am – 8:00 am</td>
<td>Mutual Help (Open Meeting)</td>
<td>Del Rio 2, Level 1</td>
</tr>
<tr>
<td>7:30 am – 7:00 pm</td>
<td>ASAM Registration Open</td>
<td>Center Pre-Function, Level 3</td>
</tr>
<tr>
<td>8:00 am – 9:00 am</td>
<td>Pre-Conference Course Continental Breakfast</td>
<td>Multiple Locations, Level 3</td>
</tr>
<tr>
<td>9:00 am – 4:30 pm</td>
<td>Pain &amp; Addiction: Common Threads Course XXV – <em>(6.00 CE)</em> Separate Registration Required</td>
<td>Grapevine CD, Level 3</td>
</tr>
<tr>
<td></td>
<td>Women &amp; Addiction: Screening, Treatment, and Whole Person Care – <em>(6.00 CE)</em> Separate Registration Required</td>
<td>Grapevine AB, Level 3</td>
</tr>
<tr>
<td>3:00 pm – 7:00 pm</td>
<td>ASAM Booth Open</td>
<td>Center Pre-Function, Level 3</td>
</tr>
</tbody>
</table>

### Annual Conference Begins

**Friday, April 5**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am – 8:00 am</td>
<td>Morning Yoga Class</td>
<td>Appaloosa 3, Level 3</td>
</tr>
<tr>
<td></td>
<td>Mutual Help (Open Meeting)</td>
<td>Del Rio 2, Level 1</td>
</tr>
<tr>
<td>7:30 am – 8:30 am</td>
<td>Continental Breakfast</td>
<td>Longhorn Hall D, Level 1</td>
</tr>
</tbody>
</table>

**Saturday, April 6**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 am – 12:00 pm</td>
<td>Keynote Address</td>
<td>Convention Center, Level 1</td>
</tr>
</tbody>
</table>

**Sunday, April 7**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 am – 12:00 pm</td>
<td>Closing Session</td>
<td>Convention Center, Level 1</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Location</td>
</tr>
<tr>
<td>--------------------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>7:30 am – 3:00 pm</td>
<td>Exhibit Hall Open</td>
<td>Longhorn Hall D, Level 1</td>
</tr>
<tr>
<td>7:30 am – 4:00 pm</td>
<td>ASAM Registration Open</td>
<td>Center Pre-Function, Level 3</td>
</tr>
<tr>
<td>7:30 am – 5:30 pm</td>
<td>ASAM Booth Open</td>
<td>Center Pre-Function, Level 3</td>
</tr>
<tr>
<td>8:00 am – 8:30 am</td>
<td>Addiction Consult Special Interest Group Meet-Up</td>
<td>Lounge 1, Longhorn Hall D, Level 1</td>
</tr>
<tr>
<td></td>
<td>Child &amp; Adolescent Addiction Special Interest Group Meet-Up</td>
<td>Lounge 2, Longhorn Hall D, Level 1</td>
</tr>
<tr>
<td></td>
<td>Meet the JAM Editors</td>
<td>Lounge 3, Longhorn Hall D, Level 1</td>
</tr>
<tr>
<td>8:30 am – 9:45 am</td>
<td>Opening General Session - Broadening Perspectives to Narrow the Treatment Gap – (1.25 CE)</td>
<td>Texas AD, Level 3 GS</td>
</tr>
<tr>
<td></td>
<td>Ricky N. Bluthenthal, PhD; Elizabeth M. Salisbury-Afshar, MD, MPH, FAAFP, FACPM, DFASAM; Marlene Martin, MD; Calla Harrington, LICSW, MPH; Hansel Tookes, MD, MPH</td>
<td></td>
</tr>
<tr>
<td>9:45 am – 10:30 am</td>
<td>Break</td>
<td>Longhorn Hall D, Level 1</td>
</tr>
<tr>
<td></td>
<td>Scientific Poster Session 1a – (0.75 CE)</td>
<td>Center Pre-Function, Level 3</td>
</tr>
<tr>
<td>10:00 am – 10:30 am</td>
<td>Harm Reduction Special Interest Group Meet-Up</td>
<td>Lounge 1, Longhorn Hall D, Level 1</td>
</tr>
<tr>
<td></td>
<td>Physician Health Special Interest Group Meet-Up</td>
<td>Lounge 2, Longhorn Hall D, Level 1</td>
</tr>
<tr>
<td></td>
<td>Social Workers Meet-Up</td>
<td>Lounge 3, Longhorn Hall D, Level 1</td>
</tr>
<tr>
<td>10:30 am – 11:45 am</td>
<td>An Overview of the Management of Benzodiazepine Use Disorder – (1.25 CE)</td>
<td>Texas 4-6, Level 3 FS</td>
</tr>
<tr>
<td></td>
<td>Logan D. Adams, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Crash Course on Co-Occurring Conditions: Psychiatric Management in Addiction Medicine – (1.25 CE)</td>
<td>Grapevine B, Level 3 WS</td>
</tr>
<tr>
<td></td>
<td>Danielle M. Gainer, MD; Brent Schnipke, MD; Daniel Fisher, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Implementing a Mobile MAT Program: Regulatory, Clinical and Other Considerations – (1.25 CE)</td>
<td>Grapevine 1-3, Level 3 FS</td>
</tr>
<tr>
<td></td>
<td>Maria Bruni, PhD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Integrating Diversity, Equity, Inclusion, and Belonging into Addiction Treatment – (1.25 CE)</td>
<td>Texas 1-3, Level 3 WS</td>
</tr>
<tr>
<td></td>
<td>Anika Alvanzo, MD, MS, FACP, DFASAM; Zina Rodriguez, MSW, MCAP, CDE; Kamala Greene Genece, PhD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Is Your Methadone Clinic Helping or Harming in the Fentanyl Era – (1.25 CE)</td>
<td>Grapevine D, Level 3 FS</td>
</tr>
<tr>
<td></td>
<td>Ruth A. Patee, MD, DFASAM; Laura Gaeta Kehoe, MD, MPH, FASAM; Zoe Weinstein, MD, MS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Non-Fatal Overdose Biosurveillance: Building a New Overdose Surveillance Infrastructure – (1.25 CE)</td>
<td>Grapevine 4-6, Level 3 FS</td>
</tr>
<tr>
<td></td>
<td>Ewa King, PhD; Charles McKay, MD, FACMT; Jill S. Warrington, MD, PhD; Amanda J. Smith, MPH</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rapid Initiation of Naltrexone and Buprenorphine: Findings from the NIDA CTN – (1.25 CE)</td>
<td>Grapevine A, Level 3 WS</td>
</tr>
<tr>
<td></td>
<td>Matisyahu Shulman, MD; Adam Bisaga, MD; Kathryn Hawk, MD, MHS</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Location</td>
</tr>
<tr>
<td>--------------------</td>
<td>------------------------------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>10:30 am – 11:45 am</td>
<td>The Clinical Consequences of Stimulant Use: Focus on Intoxication, Washout, and Therapies – (1.25 CE)</td>
<td>Texas AD, Level 3</td>
</tr>
<tr>
<td></td>
<td>JoAn Laes, MD, FACMT, DFASAM; Timothy J. Wiegand, MD, FACMT, FAACPT, DFASAM; Jeremiah D. Fairbanks, DO, DFASAM; Ian Latham, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Julie Childers, MD, FASAM; Janet J. Ho, MD, MPH; Heather Richards, MD</td>
<td></td>
</tr>
<tr>
<td>11:45 am – 1:15 pm</td>
<td>Lunch Break</td>
<td>Longhorn Hall D, Level 1</td>
</tr>
<tr>
<td>12:15 pm – 1:15 pm</td>
<td>Region III Meeting (CT, MA, ME, NH, RI, VT)</td>
<td>Austin 4-6, Level 3</td>
</tr>
<tr>
<td></td>
<td>Region IV Meeting (NJ, OH, PA)</td>
<td>Austin 1-3, Level 3</td>
</tr>
<tr>
<td></td>
<td>Region VII Meeting (AR, OK, KS, LA, MO, NE, TX)</td>
<td>San Antonio 4-6, Level 3</td>
</tr>
<tr>
<td></td>
<td>Region VIII Meeting (AK, AZ, CO, HI, ID, MT, NM, ND, NV, OR, SD, UT, WA, WY)</td>
<td>Ft. Worth 5-7, Level 3</td>
</tr>
<tr>
<td></td>
<td>Scientific Poster Session 1b – (1.00 CE)</td>
<td>Center Pre-Function, Level 3</td>
</tr>
<tr>
<td>12:30 pm – 1:00 pm</td>
<td>Criminal Justice Special Interest Group Meet-Up</td>
<td>Lounge 1, Longhorn Hall D, Level 1</td>
</tr>
<tr>
<td></td>
<td>LGBTQ+ Special Interest Group Meet-Up</td>
<td>Lounge 2, Longhorn Hall D, Level 1</td>
</tr>
<tr>
<td></td>
<td>Medical Toxicology Special Interest Group Meet-Up</td>
<td>Lounge 3, Longhorn Hall D, Level 1</td>
</tr>
<tr>
<td>1:15 pm – 2:30 pm</td>
<td>3.7R Medically Monitored Residential: Creating a Critical Service for Complex Patients – (1.25 CE)</td>
<td>Texas 4-6, Level 3</td>
</tr>
<tr>
<td></td>
<td>Eowyn Rieke, MD, MPH, FASAM; Charlotte VanCleve, MSN, PMHNPC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Always Open, Always Safe: A Blueprint for 24/7 ED Based Harm Reduction – (1.25 CE)</td>
<td>Grapevine D, Level 3</td>
</tr>
<tr>
<td></td>
<td>Josh Luftig, PA-C; Aimee Moulin, MD; Arianna D. Campbell, PA-C; Arlene Brown</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Behavioral Addictions: Not All Addictions are Substance Use Disorders! – (1.25 CE)</td>
<td>Grapevine B, Level 3</td>
</tr>
<tr>
<td></td>
<td>Emily Brunner, MD, DFASAM; Paul H. Earley, MD, DFASAM; Margaret Jarvis, MD, DFASAM; Timothy W. Fong, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bridging the Gap between Science and Clinical Practice – (1.25 CE) Developed in Collaboration with the Agency for Healthcare Research and Quality and the National Institutes of Health</td>
<td>Grapevine 1-3, Level 3</td>
</tr>
<tr>
<td></td>
<td>Wilson M. Compton, MD, MPE; Elisabeth Kato, MD, MRP; Geetha A. Subramaniam, MD, DLFAAPA, DFACAP; Aaron White, PhD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Motivational Interviewing 4 – New and Foundational Concepts – (1.25 CE)</td>
<td>Texas 1-3, Level 3</td>
</tr>
<tr>
<td></td>
<td>Carla B. Marienfeld, MD, DFAPA, FASAM; Brian Hurley, MD, MBA, FAPA, DFASAM; Caridad Ponce Martinez, MD, FASAM</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Not as Easy as 1, 2, 3: Creating an Adolescent Withdrawal Pathway – (1.25 CE)</td>
<td>Grapevine A, Level 3</td>
</tr>
<tr>
<td></td>
<td>Krishna White, MD, MPH, FASAM; Rachel Linstead Goldsmith, MPA; Frank P. James, MD, JD, FAACLM, DFASAM; Terri Randall, MD</td>
<td></td>
</tr>
</tbody>
</table>
**Friday, April 5**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:15 pm – 2:30 pm</td>
<td>Police Diversion Programs and Pre-Release Partnerships to Enhance Substance Use Treatment – (1.25 CE)</td>
<td>Grapevine 4-6, Level 3</td>
</tr>
<tr>
<td></td>
<td>Jeanmarie Perrone, MD; Dorian Jacobs, MD; Nicole O’Donnell, BA, CRS; Judy S. Chertok, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Treating Tranq: Practical Lessons from the Epicenter of the Xylazine Crisis – (1.25 CE)</td>
<td>Texas AD, Level 3</td>
</tr>
<tr>
<td></td>
<td>Bridget R. Durkin, MD, MBE; Sam Hua, MD, MPH, MS; Nia M. Bhadra-Heintz, MD, FASAM; Emily R. Casey, PharmD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>We’ve Been Doing it Wrong! Improving Methadone Restarts in the Fentanyl Era – (1.25 CE)</td>
<td>Grapevine C, Level 3</td>
</tr>
<tr>
<td></td>
<td>Joshua Blum, MD, FACP, FASAM; Alexandra R. Tillman, MS; Martin Hinrichs, MD; Hannan M. Braun, MD</td>
<td></td>
</tr>
<tr>
<td>2:30 pm – 3:00 pm</td>
<td>Refreshment Break</td>
<td>Lounge 1, Longhorn Hall D, Level 1</td>
</tr>
<tr>
<td></td>
<td>Cannabis &amp; Pregnancy Special Interest Group Meet-Up</td>
<td>Lounge 2, Longhorn Hall D, Level 1</td>
</tr>
<tr>
<td></td>
<td>Pain &amp; Palliative Care Special Interest Group Meet-Up</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Principles of Addiction Medicine Seventh Edition Book Launch</td>
<td>ASAM Booth, Center Pre-Function, Level 3</td>
</tr>
<tr>
<td></td>
<td>Students Meet-Up</td>
<td>Lounge 3, Longhorn Hall D, Level 1</td>
</tr>
<tr>
<td>3:00 pm – 4:15 pm</td>
<td>Annual Review of Addiction Medicine: Highest Impact Articles from 2023-2024 – (1.25 CE)</td>
<td>Texas AD, Level 3</td>
</tr>
<tr>
<td></td>
<td>Sarah E. Wakeman, MD, FASAM; Joshua D. Lee, MD, MSc</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Concurrent Treatment of PTSD and SUD: Prolonged Exposure vs. MDMA-Assisted Therapy – (1.25 CE)</td>
<td>Grapevine D, Level 3</td>
</tr>
<tr>
<td></td>
<td>Jeffrey Hill, MD; Jeffrey Foote, PhD; Carrie Wilkens, PhD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Drug Testing in Substance Use Disorder Treatment: Does It Help or Hurt? – (1.25 CE)</td>
<td>Grapevine 1-3, Level 3</td>
</tr>
<tr>
<td></td>
<td>Stephen Alexander Martin, MD, EdM, FAAFP, FASAM</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Improving Outcomes and Mortality from Fentanyl - MOUD Split Dose, Toxicology, Breastfeeding – (1.25 CE)</td>
<td>Grapevine C, Level 3</td>
</tr>
<tr>
<td></td>
<td>Vania P. Rudolf, MD, MPH, DFASAM; Dennis J. Hand, PhD; Elisha M. Wachman, MD; Sharon Ostfeld-Johns, MD, IBCLC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Integrating Addiction Prevention and Early Treatment in Primary Care Settings: Advances in Research and Practice – (1.25 CE)</td>
<td>Grapevine 4-6, Level 3</td>
</tr>
<tr>
<td></td>
<td>Developed in Collaboration with the National Institute on Alcohol Abuse and Alcoholism</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deidra Y. Roach, MD; Amy Leibowitz, PsyD; Pamela A. Matson, PhD, MPH; David R. Gastfriend, MD, DFASAM</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Macro-Induction of Buprenorphine in an Outpatient Virtual Setting – (1.25 CE)</td>
<td>Grapevine B, Level 3</td>
</tr>
<tr>
<td></td>
<td>J. Stryder ZoBell, MD, CCFP; Jenifer Nasr, BSc</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Overcoming OUD Treatment Barriers for People Experiencing Homelessness – (1.25 CE)</td>
<td>Grapevine A, Level 3</td>
</tr>
<tr>
<td></td>
<td>Marina Gaeta Gazzola, MD; Donnie Rose; Trish Rios; Nicholas J. Christian, MD, MBA, FASAM; Kelly Thompson, MA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Practicing Motivational Interviewing: Practice with Strategic Listening and Response – (1.25 CE)</td>
<td>Texas 1-3, Level 3</td>
</tr>
<tr>
<td></td>
<td>Carla B. Marienfeld, MD, DFAPA, FASAM; Brian Hurley, MD, MBA, FAPA, DFASAM; Caridad Ponce Martinez, MD, FASAM</td>
<td></td>
</tr>
</tbody>
</table>
## SCHEDULE

### Friday, April 5

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>CE Hours</th>
</tr>
</thead>
</table>
| 3:00 pm – 4:15 pm | **Teaming vs. “Staying in Your Lane”: Interdisciplinary Team Conflicts in Addiction Medicine** – (1.25 CE)  
Danielle M. Gainer, MD; Anna M. Squibb, MD; Isabelle Fox | Texas 4-6, Level 3 | WS       |
| 4:15 pm – 4:30 pm | **Break** | Texas Pre-Function, Level 3 |           |
| 4:30 pm – 5:30 pm | **General Session - The Future of Addiction Care: Transformed Systems, Practices, and Lives** – (1.00 CE)  
Brian Hurley, MD, MBA, FAPA, DFASAM; Corey Waller, MD, MS, FACEP, DFASAM; Lipi Roy, MD, MPH, MS, FASAM; Jasleen K. Salwan, MD, MPH, FASAM | Texas AD, Level 3 | GS       |
| 6:00 pm – 8:00 pm | **Rodeo Reception**  
*Shuttles available from Tour Lobby, Level 1*  
*Glass Cactus* | Texas AD, Level 3 |           |
| 9:00 pm – 10:00 pm | **Mutual Help (Open Meeting)** | Del Rio 2, Level 1 |           |

### Saturday, April 6

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>CE Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am – 8:00 am</td>
<td><strong>Morning Yoga Class</strong></td>
<td>Appaloosa 3, Level 3</td>
<td></td>
</tr>
<tr>
<td>7:30 am – 8:30 am</td>
<td><strong>Continental Breakfast</strong></td>
<td>Longhorn Hall D, Level 1</td>
<td></td>
</tr>
<tr>
<td>7:30 am – 1:30 pm</td>
<td><strong>Exhibit Hall Open</strong></td>
<td>Longhorn Hall D, Level 1</td>
<td></td>
</tr>
<tr>
<td>7:30 am – 2:00 pm</td>
<td><strong>ASAM Registration Open</strong></td>
<td>Center Pre-Function, Level 3</td>
<td></td>
</tr>
<tr>
<td>7:30 am – 5:00 pm</td>
<td><strong>ASAM Booth Open</strong></td>
<td>Center Pre-Function, Level 3</td>
<td></td>
</tr>
</tbody>
</table>
| 8:00 am – 8:30 am | **Nicotine & Tobacco Special Interest Group Meet-Up**  
**Residents & Fellows-in-Training Meet-Up**  
**Forensic Addiction Medicine Meet-Up** | Lounge 1, Longhorn Hall D, Level 1 |           |
| 8:30 am – 9:45 am | **Policy & Science General Session - Methadone in the Modern Era** – (1.25 CE)  
Yngvild K. Olsen, MD, MPH, DFASAM; Ruth A. Potee, MD, DFASAM; Aaron Ferguson, BS; Stephen M. Taylor, MD, MPH, DFAPA, DFASAM | Texas AD, Level 3 | GS       |
| 9:45 am – 10:30 am | **Break** | Longhorn Hall D, Level 1 |           |
| 10:00 am – 10:30 am | **Scientific Poster Session 2a** – (0.75 CE) | Center Pre-Function, Level 3 |           |
| 10:00 am – 10:30 am | **ASAM State Advocacy Collaborative Meet-Up** | Lounge 1, Longhorn Hall D, Level 1 |           |
| 10:30 am – 11:45 am | **Twelve-Step Recovery Special Interest Group Meet-Up** | Lounge 3, Longhorn Hall D, Level 1 |           |
| 10:30 am – 11:45 am | **Harm Reduction Implementation in a Rural Jail** – (1.25 CE)  
Paula Donnelly Cook, MD, FASAM; Lanette L. Denton; Shan Hackwell | Texas 1-3, Level 3 | FS       |
| 10:30 am – 11:45 am | **How to Navigate Buprenorphine Discontinuation** – (1.25 CE)  
Kento Sonoda, MD, AAHIVS, FASAM; Jennifer Bella Kruteneste, MD, MS, FASAM; Jacob P. Scheer, MD; Amy B. Hilmer, MD | Grapevine C, Level 3 | WS       |

https://annualconference.asam.org/
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 am – 11:45 am</td>
<td>Implementing Peer Supports to Maximize Treatment Outcomes – (1.25 CE)</td>
<td>Grapevine 1-3, Level 3</td>
<td>FS</td>
</tr>
<tr>
<td></td>
<td>Karen Scott, MD, MPH; Ken Shatzkes, PhD; Edward Suarez, PsyD, MBA; Jason Pritchard, CPRS, i-FPRS</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kratom: Emerging Findings and Treatment Considerations such as MI and Medication Strategies – (1.25 CE)</td>
<td>Grapevine D, Level 3</td>
<td>WS</td>
</tr>
<tr>
<td></td>
<td>Marissa Andres-Kim, MD; Iman Parhami, MD, MPH, FASAM; Brian Hurley, MD, MBA, FAPA, DFASAM</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maximally Supportive Care: Creating SUD Systems to Improve Engagement and Retention – (1.25 CE)</td>
<td>Grapevine A, Level 3</td>
<td>WS</td>
</tr>
<tr>
<td></td>
<td>Eowyn Rieke, MD, MPH, FASAM</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NIDA CTN Research Updates: Treatments for Stimulant Use Disorders – (1.25 CE) Developed in Collaboration with the National Institute on Drug Abuse</td>
<td>Texas 4-6, Level 3</td>
<td>CS</td>
</tr>
<tr>
<td></td>
<td>Geetha A. Subramaniam, MD, DLFAPA, DFAACAP; Madhukar H. Trivedi, MD; Kathleen T. Brady, MD, PhD; Rong Xu, PhD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Recognizing and Addressing Microaggressions in Treatment Groups: An Integrated Approach – (1.25 CE)</td>
<td>Grapevine 4-6, Level 3</td>
<td>FS</td>
</tr>
<tr>
<td></td>
<td>Tiffany Lee, PhD, LPC, CAADAC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Kids Are (Not) Alright: A Multidisciplinary Approach to Care for Adolescents – (1.25 CE)</td>
<td>Grapevine B, Level 3</td>
<td>WS</td>
</tr>
<tr>
<td></td>
<td>Alexander S. Golec, MD, FAAP; Erin R. McKnight, MD, MPH, FASAM; Kelsey Schmuhl, PharmD, BCACP; Audrey Knaff, MSW, LISW-S</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Treating Pain in Hospitalized Patients on MOUD – (1.25 CE)</td>
<td>Texas AD, Level 3</td>
<td>FS</td>
</tr>
<tr>
<td></td>
<td>Steven Tate, MD, MSc; Bridget R. Durkin, MD, MBE; Emily R. Casey, PharmD; Erik O. Saka, MD, MBE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45 am – 1:15 pm</td>
<td>Lunch Break</td>
<td>Longhorn Hall D, Level 1</td>
<td></td>
</tr>
<tr>
<td>12:15 pm – 1:15 pm</td>
<td>International Addiction Medicine Special Interest Group Meet-Up</td>
<td>Austin 1-3, Level 3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PA &amp; NP Meet-Up</td>
<td>Ft. Worth 5-7, Level 3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Region II Meeting (CA)</td>
<td>Austin 4-6, Level 3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Region IX Meeting (Canada/International)</td>
<td>Austin 1-3, Level 3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Region V Meeting (DE, DC, GA, MD, NC, SC, VA, WV)</td>
<td>San Antonio 1-3, Level 3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Scientific Poster Session 2b – (1.00 CE)</td>
<td>Center Pre-Function, Level 3</td>
<td></td>
</tr>
<tr>
<td>12:30 pm – 1:00 pm</td>
<td>Opioid Treatment Program Meet-Up</td>
<td>Lounge 1, Longhorn Hall D, Level 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Science Initiative Special Interest Group Meet-Up</td>
<td>Lounge 2, Longhorn Hall D, Level 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sitting for the Addiction Medicine Board Exam Special Interest Group Meet-Up</td>
<td>Lounge 3, Longhorn Hall D, Level 1</td>
<td></td>
</tr>
<tr>
<td>1:15 pm – 2:30 pm</td>
<td>Addiction Medicine in Carceral Settings across the Globe – (1.25 CE)</td>
<td>Texas 1-3, Level 3</td>
<td>FS</td>
</tr>
<tr>
<td></td>
<td>Annabel J. Mead, MBBS; Adrian Dunlop, MBBS; Jonna Levola, MD, PhD; Carl Erik Fisher, MD, FASAM</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adulterants: Lessons in History and Current Trends – (1.25 CE)</td>
<td>Texas AD, Level 3</td>
<td>FS</td>
</tr>
<tr>
<td></td>
<td>Benjamin Swart, MD; JoAn Laes, MD, DFASAM; Daniel J. Sessions, MD, FACMT, FAAEM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Location</td>
<td>Type</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td>------------</td>
<td>------</td>
</tr>
</tbody>
</table>
| 1:15 pm – 2:30 pm | *Bridge Over Troubled Waters: Crossing the Knowledge Gap in Drug Test Interpretation* – (1.25 CE)  
Jill S. Warrington, MD, PhD; Christine Snozek, PhD  
*Co-occurring Disorders: Integrating Prevention, Intervention and Evidence* – (1.25 CE) Developed in Collaboration with the Substance Abuse and Mental Health Services Administration  
Yngvild K. Olsen, MD, MPH, DFASAM; Robert Baillieu, MD, MPH, FAAFP; Christopher M. Jones, PharmD, DrPH, MPH; Neeraj Gandotra, MD  
*Innovations in Buprenorphine Initiation for the Advanced Clinician* – (1.25 CE)  
Andrew A. Herring, MD; Melissa B. Weimer, DO, MCR, DFASAM; Laura Gaeta Kehoe, MD, MPH, FASAM; Pouya Azar, MD  
*Leveraging Community Partnerships to Address Social Needs and Improve Care Engagement* – (1.25 CE)  
Robin A. Thompson, DrPH, MPH; Alecia D. Webb-Edgington; Terry Bunn, PhD; Madison Ashworth, PhD  
*Not HOCUS POCUS: Bedside U/S for the Addiction Medicine Specialist* – (1.25 CE)  
Michael Howard Baca-Atlas, MD, FASAM; Thomas Roberston, MD  
*Semaglutide Circus: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists to Treat Addiction* – (1.25 CE)  
Stephanie T. Weiss, MD, PhD; Jeffrey Brent, MD, PhD  
*Youth and Social Media: Connections to Addiction and Mental Illness* – (1.25 CE)  
Sara J. Polley, MD, FAPA, FASAM; Emily Brunner, MD, DFASAM | Grapevine D, Level 3   Texas 4-6, Level 3   Grapevine C, Level 3   Grapevine 4-6, Level 3   Grapevine A, Level 3   Grapevine B, Level 3   Grapevine 1-3, Level 3 | WS   CS   WS   FS   WS   FS   FS |
| 2:30 pm – 2:45 pm | Ice Cream Break | Texas Pre-Function, Level 3 | |
| 2:45 pm – 3:45 pm | *ASAM: State of the Organization*  
Brian Hurley, MD, MBA, FAPA, DFASAM | Texas AD, Level 3 | |
| 3:45 pm – 4:00 pm | Break | Texas Pre-Function, Level 3 | |
| 4:00 pm – 5:15 pm | *Addressing Prenatal Alcohol Exposure and Fetal Alcohol Syndrome Disorders* – (1.25 CE)  
Sherry Nykiel, MD; Omar Shah, MD  
*Are You my Person? Surrogate Decision-making in Patients with Use Disorders* – (1.25 CE)  
Ben Thompson, MD; Janet J. Ho, MD, MPH; Monika Holbein, MD; Kyle Neale, DO  
*Clinicians Advocating for Methadone Reform: Community Engagement and Empowerment* – (1.25 CE)  
Rachel Elizabeth Simon, MD; Zoe Weinstein, MD, MS; Aaron Ferguson, BSW; Nick Voyles; Kimberly L. Sue, MD, PhD; Paul J. Joudrey, MD, MPH  
*HIV PrEP for People Who Use Drugs* – (1.25 CE)  
Kento Sonoda, MD, AAHIVS, FASAM; Francesco Tani, DO  
*Implementation of a Statewide Network Scales Addiction Care for Underserved Populations* – (1.25 CE)  
Gabriela Castro, MD; Orrin D. Ware, PhD, MPH, MSW; Robyn Jordan, MD, PhD | Grapevine C, Level 3   Grapevine B, Level 3   Texas 4-6, Level 3   Grapevine A, Level 3   Grapevine 1-3, Level 3 | WS   WS   FS   WS   FS |
### Saturday, April 6

**4:00 pm – 5:15 pm**

**Making Addiction Treatment Primary: Enhancing Addiction Medicine Services in Primary Care** – *(1.25 CE)*
Zachary Sartor, MD, FAAFP; Jose R. Pena, DO, FM-OB; Melissa Esparza, CCMA; Jacqueline Orler, LCSW; Ryan Laschober, MD, FAAFP

**Prescribing Medications for Alcohol Use Disorder for Individuals with Liver Disease** – *(1.25 CE)* Developed in Collaboration with the Providers Clinical Support System - Medications for Alcohol Use Disorder
Melissa B. Weimer, DO, MCR, DFASAM; Stephen Holt, MD, MS, FACP, FASAM

**Tidbits of Toxicity: Exploring Effects of Ketamine, Psilocybin, and Other Psychedelics** – *(1.25 CE)*
JoAn Laes, MD, DFASAM; Ian Latham, MD; Evan S. Schwarz, MD; Jeremiah D. Fairbanks, DO, FASAM; Robert Cole Pueringer, MD, FASAM

**5:15 pm – 6:00 pm**

**Book Signing with Gabrielle Jones, PhD**
ASAM Booth, Center Pre-Function, Level 3

**5:30 pm – 6:30 pm**

**Region I Meeting (NY)**
Austin 4-6, Level 3

**Region VI Meeting (IA, IL, IN, MI, MN, WI)**
Ft. Worth 5-7, Level 3

**7:00 pm – 9:00 pm**

**Movie Night - Our American Family** – *(2.00 CE)*
Linda (Mom); Stephen (Son)
Grapevine C, Level 3

**9:00 pm – 10:00 pm**

**Mutual Help (Open Meeting)**
Del Rio 2, Level 1

### Sunday, April 7

**7:00 am – 8:00 am**

**Mutual Help (Open Meeting)**
Del Rio 2, Level 1

**Ruth Fox Endowment Scholarship Recipients Meeting**
Austin 1-3, Level 3

**7:30 am – 8:30 am**

**Continental Breakfast**
Grapevine Pre-Function, Level 3

**7:30 am – 10:00 am**

**ASAM Registration Open**
Center Pre-Function, Level 3

**7:30 am – 11:30 am**

**ASAM Booth Open**
Center Pre-Function, Level 3

**8:30 am – 9:45 am**

**Cured! The Role of the Psychiatrist in the Treatment of Hepatitis C** – *(1.25 CE)*
Sherry Nykiel, MD; Vishesh Agarwal, MD

**Housing for People with Substance Use Disorders: Best Practices, Innovations, and Gaps** – *(1.25 CE)*
Elizabeth M. Salisbury-Afshar, MD, MPH, FAAFP, FACPM, DFASAM; Sarah Holland, MSW, MPH; Gordon Keepers, LCSW

**Methadone Dispensing at Acute Care Discharge: Implementing the New 72-Hour Rule** – *(1.25 CE)*
Megan Buersch, MD, DFASAM; Melissa B. Weimer, DO, MCR, DFASAM; Elaine Huang, PharmD, MHA; Elenore Bhattacharji, MD, MPH

**7:00 am – 8:00 am**

**Mutual Help (Open Meeting)**
Del Rio 2, Level 1

**ASAM Booth Open**
Center Pre-Function, Level 3

**8:30 am – 9:45 am**

**Ruth Fox Endowment Scholarship Recipients Meeting**
Austin 1-3, Level 3

**Continental Breakfast**
Grapevine Pre-Function, Level 3

**ASAM Registration Open**
Center Pre-Function, Level 3

**ASAM Booth Open**
Center Pre-Function, Level 3

**Cured! The Role of the Psychiatrist in the Treatment of Hepatitis C** – *(1.25 CE)*
Sherry Nykiel, MD; Vishesh Agarwal, MD

**Housing for People with Substance Use Disorders: Best Practices, Innovations, and Gaps** – *(1.25 CE)*
Elizabeth M. Salisbury-Afshar, MD, MPH, FAAFP, FACPM, DFASAM; Sarah Holland, MSW, MPH; Gordon Keepers, LCSW

**Methadone Dispensing at Acute Care Discharge: Implementing the New 72-Hour Rule** – *(1.25 CE)*
Megan Buersch, MD, DFASAM; Melissa B. Weimer, DO, MCR, DFASAM; Elaine Huang, PharmD, MHA; Elenore Bhattacharji, MD, MPH

**7:00 am – 8:00 am**

**Mutual Help (Open Meeting)**
Del Rio 2, Level 1

**Ruth Fox Endowment Scholarship Recipients Meeting**
Austin 1-3, Level 3

**Continental Breakfast**
Grapevine Pre-Function, Level 3

**ASAM Registration Open**
Center Pre-Function, Level 3

**ASAM Booth Open**
Center Pre-Function, Level 3

**Cured! The Role of the Psychiatrist in the Treatment of Hepatitis C** – *(1.25 CE)*
Sherry Nykiel, MD; Vishesh Agarwal, MD

**Housing for People with Substance Use Disorders: Best Practices, Innovations, and Gaps** – *(1.25 CE)*
Elizabeth M. Salisbury-Afshar, MD, MPH, FAAFP, FACPM, DFASAM; Sarah Holland, MSW, MPH; Gordon Keepers, LCSW

**Methadone Dispensing at Acute Care Discharge: Implementing the New 72-Hour Rule** – *(1.25 CE)*
Megan Buersch, MD, DFASAM; Melissa B. Weimer, DO, MCR, DFASAM; Elaine Huang, PharmD, MHA; Elenore Bhattacharji, MD, MPH
## SCHEDULE

### Sunday, April 7

#### 8:30 am – 9:45 am

**Naloxone, Nalmefene, and Naltrexone: Is There a Need for Three Opioid Antagonists? – (1.25 CE)**
Developed in Collaboration with the American College of Medical Toxicology
Lewis S. Nelson, MD, MBA, FASAM; Evan S. Schwarz, MD; JoAn Laes, MD, DFASAM; Robert Cole Pueringer, MD, FASAM

**SBIRT™: Incorporating Harm Reduction Strategies into the SBIRT Model – (1.25 CE)**
Namrata Walia, MD, MPH, MHA; Michael F. Weaver, MD, DFASAM; Daryl Shorter, MD

**Treating Stimulant Use Disorder – Updates from the ASAM/AAAP National Practice Guideline – (1.25 CE)**
Brian Hurley, MD, MBA, FAPA, DFASAM; Larissa Mooney, MD

#### 9:45 am – 10:15 am

**Break**

#### 10:15 am – 11:30 am

**Demonstrating the MI Spirit with Complex Reflections: A Motivational Interviewing Workshop – (1.25 CE)**
Julie Childers, MD, FASAM; Caridad Ponce Martinez, MD, FASAM; Carla B. Marienfeld, MD, DFAPA, FASAM

**Facilitating the Transition from Hospital to Sub-Acute Residential Care – (1.25 CE)**
Corey Waller, MD, MS, FACEP, DFASAM; Anika Alvarado, MD, MS, FACP, DFASAM; Jason Kirby, DO, MBA, FASAM; Debra Nussbaum, PhD, LCSW

**Intervention to Address Healthcare Worker Based Stigma in Hospitals – (1.25 CE)**
Arianna D. Campbell, PA-C; Kari Herbert, SUN, CADC-II; David Jay, PhD

**Low-threshold, Complex Outpatient Withdrawal Management in Resource Limited Communities – (1.25 CE)**
Sarah Spencer, DO, FASAM

**Sedative Use Disorder: Reviewing Best Practice Models of Care and Taper Strategies – (1.25 CE)**
Christopher Milburn, MD; Christina Ferrari, MD; Xin Gao, PharmD, MSc; Carley Schaffer, MS, LCADC, CCTP, CCS

**Separated at Birth: Rethinking the Urine Drug Screen in Pregnancy – (1.25 CE)**
Elizabeth Kravitz, MD; Nia M. Bhadra-Heintz, MD, FASAM

---

End of the ASAM 55th Annual Conference.
See you next year in Denver, CO from April 24-27, 2025!

---

**Joint Accreditation Statement**
In support of improving patient care, the American Society of Addiction Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**AMA Credit Designation Statement**
The American Society of Addiction Medicine designates this live activity for a maximum of 20 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. More credit information is available online.

More credit information available online.
SCIENTIFIC POSTERS

Full poster information (including author information, poster PDFs, and more) is available on the conference website (https://annualconference.asam.org/) and in the ASAM Events app.

POSTERS 1 - 56

1 – Nicotine Use and Patient Directed Discharge Rate in Psychiatric Inpatient Steven Sprenger, MD

2 – Addressing the Whole Patient: Examination of Smoking Policies in SUD Treatment Facilities Alison G. Holt, MD

3 – Substance Use Treatment Utilization Among Community-Supervised Individuals at Risk for HIV Anna B. Parisi, PhD, MSW, LCAS; Anne Peacock, MSW

4 – Unveiling Predictors and Impact: Harm Reduction Vending Machines in Clark County, NV Rachel Q. Bryant, MPH

5 – Models for Accessing Harm Reduction Vending Machines: An Interrupted Time Series Design Ashleigh N. Herrera, PhD, MSW, LCSW

6 – Racial Disparities in M OUD Initiation Among Medicaid Patients with Infective Endocarditis Mercy Ude, MD

7 – Outcomes of an Inpatient Microinduction Cross Taper Protocol, Results After 700+ Attempts Robert Parangi, MD

8 – Breastfeeding in Postpartum Patients with Opioid Use Disorder Emily H. Stetler, MPH

9 – AnyTime, AnyWhere: Examining Low-Barrier Buprenorphine for Post Incarcerated Individuals Vivian N. Kali, MD; Thomas Robertson, MD, FACP

10 – Exploring Unintended Pregnancy Among Patients with Opioid Use Disorder Kelley J. Harmon, DO

11 – Associations between Gender and Prevalence of Daily Cannabis Use from 2008-2019 Joshua A. Hill, MD

12 – Insurance and Racial/Ethnic Disparities in Receipt of Medications for Alcohol Use Disorder Carrie M. Mintz, MD

13 – Contraceptive Uptake in Postpartum People with and without Opioid Use Disorder Jennifer Bello Kottenstette, MD, MS, FASAM; Kevin Y. Xu, MD

14 – Comorbid Substance Use Disorders in Individuals with Diagnosed Eating Disorders Dominic Moog; Binx Y. Lin, MD, MSc;

15 – Characterization of Young Adults Accessing Buprenorphine Telehealth in Philadelphia, PA Maria C. Herrera, MD, MSHP; Nicole O’Donnell, CRS; Jasmine Barnes, MPH

16 – ASAM Criteria-based Standardized Recommendations and Discrepancies with Actual Referrals David R. Gastfriend, MD, DFASAM

17 – Keeping Patients in Care?: Factors Associated with Patients Returning to Care Phyllis Loskoff, MD

18 – Transition from Sublingual to LA Injectable Buprenorphine Best Practices Phyllis Loskoff, MD; Sally Combest, MD

19 – Dosing to effect with Subcutaneous and Sublingual Buprenorphine for Opioid Use Disorder Michael P. Frost, MD, FACP, DFASAM

20 – Low-Dose Buprenorphine Induction Protocols for Co-Occurring Pain and Opioid Use Disorders Isabelle Seto, MD

21 – State Office-based Buprenorphine Treatment Laws: Counseling, Dosage, and Visit Frequency Barbara Andrekta-Christou, JD, PhD

22 – Effect of Buprenorphine/Naloxone and Methadone on Methamphetamine/Amphetamine Use Jenna Langlois; Nadia Fairbairn, MD, MHSc

23 – The Impact of Mandatory Buprenorphine Training for Emergency Medicine Residents Jessica Heil, MS; Rachel Haroz, MD, FAACT; Matthew Salzman, MD, MPH

24 – Naloxone Use and Knowledge from Patients Treated for Opioid Use Disorder Scott G. Weiner, MD, MPH, FASAM

25 – Patient Experiences with Telehealth Treatment for Opioid Use Disorder in Alabama Scott G. Weiner, MD, MPH, FASAM

26 – Overdose after Medication for Opioid Use Disorder Initiation Following Hospitalization Scott G. Weiner, MD, MPH, FASAM

27 – Pilot Study Comparing Traditional to Low-Dose Initiation with Buprenorphine Scott G. Weiner, MD, MPH, FASAM

28 – Neurocognitive Disorder and Exposure to Medication for Opioid Use Disorder Molly M. Perri, MD; Andrea J. Landi, MD

29 – Prioritizing Integration of Prescription Drug Monitoring Program into the EHR Diana Chen, MD, MBA

30 – A Medications for Addiction Treatment (MAT) Release Program in the CDOC Jessica Krueger, MD; Atinuke Oluwatimilehin, PharmD, BCPS

Award Winner: Fellows-in-Training

Award Winner: Best Overall

Award Winner: Associated Professional

Award Winner: Underserved Population

Honorable Mention: Resident
SCIENTIFIC POSTERS

POSTERS 1 - 56  |  Friday, April 5, 2024 | Center Pre-Function, Level 3  
9:45 am – 10:30 am & 12:15 pm – 1:15 pm

31 – Increasing Dual Nicotine Replacement Prescribing within a Large Integrated Health System  
Payam Saezegar, MD, FASAM; Alaina Martinez, MD

32 – Enhancing Clinical Decision Support for Low-Threshold MAUD Prescribing in Primary Care  
Payam Saezegar, MD, FASAM

33 – Integration of Long-acting Injectable PreP with MAT: A Pre-implementation Study  
En-Ling Wu, MD; Rosa M. Malave, BSN, RN, CARN

34 – Impact of Telehealth on Visit Attendance for Women with Opioid Use Disorder  
Nancy S. Yang, MD

35 – Consent First: Reviewing a Urine Drug Screening Protocol on Labor and Delivery  
Nancy S. Yang, MD; Silvia Bastea, MD

Award Winner: Resident

36 – Impact of Addiction Consult Social Workers on Hospital Readmission Rates  
Hayley Rotello, LCSW

37 – Administration and Prescribing of Medications for Alcohol Use Disorder During COVID-19  
Christine Ramdin, PhD

38 – Getting Well: Expanding Tools to Treat Opioid Use Disorder In the Hospital  
Olivia Duffield; Sam J. Stern, MD

Honorable Mention: Student

39 – Linking Hospitalized People with OUD to Treatment: Findings from a Multisite RCT  
Stephen Ryzewicz, MD, FACP, DFASAM

40 – Pilot Trial of a Digital Health Intervention for Opioid Use Disorder  
Kirsten Langdon, PhD

41 – Xylazine Test Strip Performance in Synthetic and Human Urine Biospecimens  
Daisy M. Unshuay Vila, PhD

Honorable Mention: Associated Professional

42 – Characterization of Patient-Directed Discharge in Patients with Substance Use Disorder(s)  
Elijah T. Myers, PharmD, MBA; Megan Buresh, MD, DFASAM; Rosalyn Stewart, MD, MS, MBA

43 – Improving Linkage to Addiction Treatment with Extended-release Naltrexone  
Lisa W. Vercollone, MD, PharmD

44 – Non-Clinical Barriers and Facilitators to Treatment for Youth Who Use Opioids  
Lauren A. Bell, MD, MPH; Safina Adatia, MD, MSc; Jayla French

45 – Urine Drug Screening in a Telehealth Setting for Opioid Use Disorder Treatment  
Adam Bisaga, MD

46 – Rapid Conversion of High Dose Methadone to Buprenorphine Due to Persistent Hypoglycemia  
Nathan Menke, MD, PhD

47 – Gas Station Heroin: Tianeptine, a Unique Tricyclic Antidepressant –  
Alman B. Khalid, MD; Justin Scarano; Lucy Guevara, MD, MPH; Anna Belyayeva, DO

48 – Opportunities for Harm Reduction: Multi-domain Needs Assessment of Unhoused Individuals  
Josiah Willingham; Tyler J. Varisco, PharmD, PhD

49 – Using Interpretable Machine Learning to Predict Access to Buprenorphine in Pharmacies  
Tyler J. Varisco, PharmD, PhD

50 – Reduced Robo-Readmissions: Buprenorphine For Dextromethorphan Use Disorder  
Sorina Torrez, PharmD; John Weems-Embers, MD, FASAM; Matt Hunt, NP-C, CARN-AP

51 – Extended-Release Injectable Buprenorphine For Same-Day Induction – A Case Series  
Ellen Mooney, DO

52 – Accelerated Inpatient Transition from Methadone to Long-Acting Injectable Buprenorphine  
Tiffany Tahata, DO; Clarissa O’Conor, MD; William Ward, MD

53 – Rapid Low-Dose – High-Dose Buprenorphine Initiation Using PO Methodology - Case Series  
Edmond Hakimi, DO

54 – High Dose Buprenorphine Induction Precipitating Non-Cardiogenic Pulmonary Edema  
Daniel Liauw, MD, MPH; Evan Gale, MD, FASAM

55 – Fentanyl to Buprenorphine < 24 Hours - Rapid Microinduction Buprenorphine Initiation  
Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM

56 – Nonpharmacologic Interventions Ameliorate Withdrawal Signs in Opioid-Dependent Adults  
Stephanie T. Weiss, MD, PhD
SCIENTIFIC POSTERS

POSTERS 57 - 114 | Saturday, April 6, 2024 | Center Pre-Function, Level 3
9:45 am – 10:30 am & 12:15 pm – 1:15 pm

57 – Stuck in a Ketamine Use Cycle: Anxiety, Cystitis, and Pain
Yonina Mar, MD

58 – Getting Creative with Alpha Agonists: Xylazine Withdrawal in the Outpatient Setting
Roshni Gandhi; Mollie B. Nisen, MD

Giovani V. Cruz Cruz, MD; Jessica A. Wang, MD, MPH

60 – Buprenorphine Dose and Dosing Frequency Must Be Increased During Pregnancy
Raman Venkataramanan, PhD

61 – Comparison of Opioid and Alcohol Use Disorders in an Urban Health System
Alexandra R. Tillman, MS

62 – Disparities in Identification and Treatment of Opioid Use Disorder in Primary Care
Kimesha Grant, DNP(C), MPH, BSN, RN

63 – Exploring the Relationship Between Coping and Relapse with People Who Use Opioids
Abigail Gazvoda, MEd, LPC

64 – Higher Substance and Opioid Use Disorder in Lean Patients with MASLD
Pooja Rangan, MBBS, MPH; Majd B. Aboua, MD; Claire Faulkner

65 – Nurse Practitioner Treatment of Opioid Use Disorder: A Phenomenographic Study
Martha M. Whitfield, PhD, APRN, FNP-BC

66 – Predicting Fentanyl Use for Patients in Treatment for Opioid Use Disorder
Matthew Hanauer, MPA, PhD

67 – Self-reported Tianeptine Experiences: A Mixed-Methods Study of Reddit Users
Rachel S. Wightman, MD, FACMT; Jeanmarie Perrone, MD

68 – Which Should You Order? Blood vs. Urine Toxicology LC-QTOF-MS Testing
Sonja G. Kapadia

69 – Associations Between Umbilical Cord Drug Testing Results and PHQ-9 Scores (Pilot Study)
Abby Davison

70 – Clinically Actionable Newborn Toxicology Results are Uncommon Under New Policy
Gina Liu, MSc

71 – Healthcare Experiences of Pregnant Persons with Opioid Use Disorder: A Mixed-Methods Analysis
Jasmine Myrick; Christina Chin, LCSW

72 – Racial Disparities in Substance Use Treatment and Perinatal Outcomes for Pregnant Women
Irena Kuan; Justine Keller, MD

73 – Racial Inequity in Newborn Drug Testing Despite Universal Prenatal Substance Use Screening
Alexandra Soos; Lauren Oshman, MD, MPH

74 – Treating Opioid Use Disorder in the Peripregnancy Period on Labor and Delivery
Melanie A. Rader; Dominika Seidman, MD, MAS

75 – Impact of Opioid and Stimulant Co-Use on Perinatal Outcomes
Kristin C. Prewitt, MD, MPH

76 – Association of Substance Use and Perinatal Mood and Anxiety Disorders in Pregnancy
Erin C. Nacev, MD, MPH

77 – Maternal and Neonatal Outcomes in an Integrated Substance Use Disorder Treatment Program
Macy Afsari; Alesha M. White, MD

78 – Navigating Discrimination: Experiences of Pregnant Patients with Opioid Use Disorder
Karampreet Kaur, MD

79 – Postpartum Interpersonal Violence among Individuals with Opioid Use Disorder
Lauren T. Narbey, Ph.D, MSN, MSc, CNM, WHNP-BC, FACNM

80 – PTSD Symptomatology Associated with Insomnia Severity Among Women Receiving Buprenorphine
Hannah E. Stadtler; Susie Turkson, MS; Caitlin E. Martin, MD, MPH, FACOG, FASAM

81 – Methadone Take-Home Flexibilities and Mortality: Permitting vs. Non-Permitting States
Rebecca A. Harris, MD, MSc

82 – Organization of Primary Care and Early MOUD Discontinuation
Rebecca A. Harris, MD, MSc

83 – Fentanyl Test Strip Distribution Among Patients with Substance-Related ED Visits
Allison Kannam; Howard Kim, MD, MS

84 – Fentanyl Test Strip Distribution in the Emergency Department: Early Experience and Outcomes
Charles Reznikoff, MD, FACP, FASAM

85 – Patient Perspectives on Hospital Initiation of Long-Acting Injectable Buprenorphine
Clarissa O’Conor, MD; Aria Armstrong; Shai Farhi, MD

86 – Inpatient Initiation of Long-Acting Injectable Buprenorphine: A Case Series
Clarissa O’Conor, MD; Shai Farhi, MD

87 – Availability of Medications for Alcohol Use Disorder in Substance Use Treatment Facilities
Christine Ramdin, PhD

88 – Harm Reduction among Cisgender Gay and Bisexual Men using Anabolic Androgenic Steroids
Eric Kutscher, MD

89 – Perceived Risks of Psychedelics in Individuals with Substance Use and Psychiatric Disorders
Alexander C. Wu; Joji Suzuki, MD

90 – Cannabis and Nicotine Use: Coping Mechanisms Among LGBTQIA+ College Students
Alexa Knippenberg; Tara G. Bautista, PhD
91 – Factors Predicting MOUD Access for (Un)housed Patients: A Machine Learning Approach
Aaron Esguerra; Thomas J. Weinandy, PhD

92 – Military and Veteran Intensive Clinical Program with Alcohol and Substance Use Treatment
Sofia E. Matta, MD

93 – Factors Influencing Self-Help Group Attendance in Veterans with Substance Use Disorders
Andrew Ingrassia, MSW

94 – The Evolution of Attitudes Towards Substance Use Disorder Throughout Medical Education
Heather Kettlewell; Brady Heward, MD

95 – Perspectives from Hospitalized Patients with Substance Use Disorders: A Qualitative Study
Evan Balmuth; David Scales, MD, PhD

96 – Caring for Patients Hospitalized with Injection-related Severe Bacterial Infections
Giselle Appel; Shashi N. Kapadia, MD

97 – Brief Assessment of Recovery Capital Linked to Treatment Completion Among Hispanics
Kurt D. Lebeck, RN, RPN, MScN-FNP

98 – Tracking Cotinine: Screening for Tobacco Use in Hospitalized Pediatric Patients
Alexander S. Golec, MD, FAAP

99 – Xylazine Usage and Awareness among People who use Drugs in Denver, Colorado
Marina D. Yamada; Brittany Quinn; Sophie Zachary, OMS-II; Megan E. Schrage

100 – Xylazine Wound Care Among PWUD Accessing Massachusetts Syringe Service Programs
Samia A. Ismail; Margaret Shang, MD; Raagini Jawa, MD, MPH, FASAM

101 – Induction onto Buprenorphine Utilizing Transdermal Patches Over 24-48 Hours: IPPAS Method
Jennifer Bramley, RN, RPN, MScN-FNP; Victor W. Li, MD, PhD; Mohammadali Nikoo, MD, PhD; Jessica Machado, RN, MSN

102 – Do Payment Modalities Incentivize Screening for Unhealthy Alcohol Use in Ambulatory Care?
Aryn Phillips, PhD; Sun Jung Yoon, MS

103 – Perceptions of MOUD Among Peer Recovery Supporters: A Qualitative Study
Isabelle Fox; Sydney M. Silverstein, PhD

104 – Stakeholder Insights on Improving Care for Trauma Patients Who Use Methamphetamine
Josiah D. Morita; Nicholas Schumann, PsyD

105 – The Impact of Street Medicine and Mobile Clinics for Persons Experiencing Homelessness
Rebekah Kaufman, MS

106 – Primary Care Addiction Consultation Service: Colorado’s Implementation Support Project
David Mendez, MD, FASAM

107 – New Program Changes Utilization Patterns for Patients with Substance Use Disorders
Ashley Curry, MD; Allison Forrest, LCSW, LAC

108 – Infective Endocarditis in the Overdose Crisis: Addiction Care and Healthcare Utilization
Eva J. Farkas; Victoria Molina, DO

109 – An Atypical Case of Internet-Mediated Nootropic Use Disorder Involving Kratom and Phenibut
Ajit Deshpande, MD

110 – Rapid Transition from High Dose Methadone to Long-Acting Injectable Buprenorphine
Cassandra Chioma, MD

111 – Harm Reduction Street Outreach Clinical Services: A Case Study
Meredith Kerr, DNP, CRNP, FNP-C

112 – Buprenorphine Microinduction in an Intubated and Sedated Patient
Jessica C. Moore, MD

113 – Use of Diverted Buprenorphine before Starting Telehealth Opioid Use Disorder Treatment
Scott G. Weiner, MD, MPH, FASAM

114 – Treatment of Poppy Seed Tea Dependence with Buprenorphine in a Telehealth Practice
Amelia Burgess, MD
Annual Award Recipients

John P. McGovern Award
Petros Levounis, MD, MA, DFASAM
*Presented at the Opening General Session*

R. Brinkley Smithers Award
Yngvild K. Olsen, MD, MPH, DFASAM
*Presented at the ASAM: State of the Organization Session*

Annual Award
Anthony Albanese, MD, DFASAM
*Presented at the ASAM: State of the Organization Session*

Promotion of Inclusion, Diversity, Equality, and Justice in Addiction Medicine Award
Gabrielle Jones, PhD
*Presented at the ASAM: State of the Organization Session*

Training Director Award
Scott A. Teitelbaum, MD, DFASAM
*Presented at the ASAM: State of the Organization Session*

Public Policy Award
Senator Edward Markey (D-MA)
*Presented at the Policy & Science General Session*

Media Award
Teri Sforza
*Presented at the ASAM: State of the Organization Session*

Ruth Fox Scholars
Abdul Alim, MD
Tiffani Berkel, MD
Madeleine Eicher, MD
Noah Figman, MD
Marina G. Gazzola, MD
Ian Latham, MD
Danny Lee, MD
Daniel Liauw, MD
Nicholas O. Meade, DO
Abigail Moeller, DO
Samuel Nwaobi, MD
Adeolu O. Oladunjoye, MD
Kwadwo Owusu-Boaitey, MD
Kristin Prewitt, MD
Emily Regier, MD
Ruchi Shah, DO
Nancy Shenoi, MD
Steven Sprenger, MD
Ram Sundaresh, MD, MS
Tiffany Tahata, DO
Bryce de Venecia, MD
Jessica Wang, MD

NIDA Young Investigator Travel Award Recipients
Loretta O. Akpala, MD
Shraddha Damaraju, MD
Allison Kannam
Gina Liu
Brian McAllister
Patricio Ruano
Claire Simon
Martha Whitfield
ASAM AWARDS

Abstract Award Recipients
Presented at the ASAM: State of the Organization Session

Abstract Award: Best Overall
Scott Weiner, MD, MPH, FASAM

Abstract Award: Resident
Nancy Yang, MD

Abstract Award: Associated Professional
Barbara Andraka-Christou, JD, PhD

Abstract Award: Student
Josiah Morita

Abstract Award: Fellow-in-Training
Diana Chen, MD, MBA

Abstract Award: Underserved Population
Carrie Mintz, MD

Abstract Award: Representation in Research
Maria Herrera, MD, MSHP

Abstract Award Honorable Mentions

Honorable Mention: Associated Professional
Daisy Unsihuay Vila, PhD

Honorable Mention: Resident
Vivian Kalu, MD

Honorable Mention: Student
Olivia Duffield

Honorable Mention: Student
Eva Farkas

2024 Distinguished Fellows
Sharone A. Abramowitz, MD, DFASAM
Keyghobad Farid Araki, MD, FRCPC, DFASAM
John R. Brooklyn, MD, DFASAM
J. Luke Engeriser, MD, DFASAM
Aaron D. Fox, MD, DFASAM
Mitika Kanabar, MD, DFASAM
Lewis S. Nelson, MD, MBA, DFASAM
Ruth Potee, MD, DFASAM
Olapeju Simoyan, MD, MPH, BDS, FAAFP, DFASAM
John Symeonides, MD, DFASAM
Give Hope Now!

The Give Hope Now Initiative
An effort to empower clinicians in helping patients transform their lives.

Your gift helps to...

Encourage Careers in Addiction Medicine
- Fund more Ruth Fox Scholars
- Sustain and increase newly established DEI travel awards
- Grow reach and influence of National Addiction Treatment Week

Increase Patient Impact through Evidence
- Fund additional systematic evidence reviews, clinical guideline writing, and open access
- Support guideline translation into requested languages for underserved communities

Develop Law and Policy Initiatives
- Fund development of policies and resources to aid clinicians in navigating legal and regulatory challenges associated with treating patients with substance use disorders with controlled medications
- Support building an advocacy campaign focused on eliminating the Medicare coverage gap for residential substance use disorder services

Our Funds

The Treat Addiction Save Lives Fund
This unrestricted fund provides ASAM with the flexibility and resources it needs to respond proactively and provide solutions to challenges related to the disease of addiction.

The Ruth Fox Endowment Fund
Builds a sustainable funding source to support the ability to respond to major changes and pursue opportunities to grow including scholarships and awards.

Ways to Give
- One-Time or a Monthly Donation
- Donor-Advised Funds (DAF)
- Matching Gifts
- Life Insurance or Gifts of Stock*
- Qualified Charitable Distribution*
- Will or Trust*

*Please check with a financial advisor for specific details.

Rebecca Yannopoulos, CFRE
RYannopoulos@ASAM.org
301.392.2401

Donate now at
www.ASAM.org
CLAIMING CREDIT:
Claim credit anytime between April 8, 2024 and April 8, 2025.

Annual Conference and Pre-Conference Course Registrants:
1. Type https://eLearning.ASAM.org into your web browser.
2. Log in to the eLearning Center (eLC), using your ASAM.org username and password. This will be the same username and password that you used to register for the conference/pre-conference course.
3. After logging in, select “My Dashboard” from the top menu. On mobile devices, you will find "Dashboard" by clicking the three horizontal lines in the header.
4. Under the section titled “On-Demand Products,” locate and select the product titled “Evaluation & Certificate - Live Attendees of [the Annual Conference or Pre-Conference Courses].”
5. Select the box labeled “Complete Evaluation” and click the button that says, “Fill out Survey.”
6. After you have completed the evaluation, select the box labeled “Claim Credit & Certificate” and click the button that says, “Claim Medical Credits.”
7. Select your provider type and the number of hours you attended, then click “Submit.”
8. Print out your certificate or save it on your device.

WATCHING SESSIONS ON-DEMAND: 
Available May 6, 2024 to May 6, 2027.
Relive the conference or catch sessions you missed! Full registrants of ASAM 55th Annual Conference and Pre-Conference Courses receive complimentary access to their respective sessions on-demand in the ASAM eLearning Center. Others not registered for the ASAM 55th Annual Conference or the Pre-Conference Courses may purchase sessions on-demand in the ASAM eLearning Center when they become available.

Looking for more session information?
The full conference schedule including updates, onsite changes, speaker information, presentation slides, and more is available on the conference website annualconference.asam.org and in the ASAM Events app.

1. Download “ASAM Events” in the App Store or Google Play
2. Click on “ASAM Annual 2024”
3. Create a new account

**APP TIPS**
- Everyone will need to create a new account the first time they open the ASAM Annual 2024 event within the app. The new account does not need to have the same email address as was used during registration.
- If you want to log in to your account on multiple devices, use the password that was emailed to you after you created your account.
- To sync with updated conference info, locate and click the refresh app icon in the footer bar.
Don't miss a single booth or activity!

Familiarize yourself with the schedule and floor plan with our Sponsor & Exhibitor Guide. This serves as the ultimate roadmap to help you navigate the Exhibit Hall and make the most of your visit, as well as recognize the supporters who helped make this event happen!